Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (EP3283087) METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR ENDOCRINE SYSTEM CONDITIONS

Office : European Patent Office
Application Number: 16780681 Application Date: 13.04.2016
Publication Number: 3283087 Publication Date: 21.02.2018
Publication Kind : A4
Prior PCT appl.: Application Number:US2016027378 ; Publication Number: Click to see the data
IPC:
A61K 35/741
C12Q 1/68
G01N 33/48
G01N 33/569
G16H 50/20
G16H 50/50
G16H 50/70
[IPC code unknown for A61K 35/741]
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
569
for micro-organisms, e.g. protozoa, bacteria, viruses
[IPC code unknown for G16H 50/20][IPC code unknown for G16H 50/50][IPC code unknown for G16H 50/70]
CPC:
A61K 35/741
A61K 2035/115
G16B 20/00
G16B 40/00
G16H 50/20
G16H 50/50
G16H 50/70
Y02A 90/26
Applicants: UBIOME INC
Inventors: APTE ZACHARY
ALMONACID DANIEL
RICHMAN JESSICA
BEHBAHANI SIAVOSH REZVAN
Priority Data: 201562147058 14.04.2015 US
201562147107 14.04.2015 US
201562147202 14.04.2015 US
201562147226 14.04.2015 US
201562147304 14.04.2015 US
201562147348 14.04.2015 US
201562147355 14.04.2015 US
2016027378 13.04.2016 US
Title: (DE) VERFAHREN UND SYSTEM FÜR MIKROBIOMDERIVIERTE DIAGNOSTIKA UND THERAPEUTIKA FÜR ERKRANKUNGEN DES ENDOKRINEN SYSTEMS
(EN) METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR ENDOCRINE SYSTEM CONDITIONS
(FR) PROCÉDÉ ET SYSTÈME DE DIAGNOSTICS ET DE TRAITEMENTS DÉRIVÉS DU MICROBIOME POUR DES DYSFONCTIONNEMENTS DU SYSTÈME ENDOCRINIEN
Abstract:
(EN) A method for at least one of characterizing, diagnosing, and treating an endocrine system condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the endocrine system condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the endocrine system condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.
(FR) L'invention concerne un procédé de caractérisation et/ou de diagnostic et/ou de traitement d'un dysfonctionnement du système endocrinien chez au moins un patient, le procédé comprenant les étapes consistant : à recevoir un ensemble agrégé d'échantillons biologiques provenant d'une population de patients ; à générer au moins un ensemble de données sur la composition du microbiome et/ou un ensemble de données sur la diversité fonctionnelle du microbiome pour la population de patients ; à caractériser le dysfonctionnement du système endocrinien sur la base de caractéristiques extraites de l'ensemble de données sur la composition du microbiome et/ou de l'ensemble de données sur la diversité fonctionnelle du microbiome ; générer, sur la base de cette caractérisation, un modèle thérapeutique conçu pour corriger le dysfonctionnement du système endocrinien ; et promouvoir auprès du sujet, sur un dispositif de sortie qui lui est associé, un traitement sur la base de la caractérisation et du modèle thérapeutique.